Novel combination chemotherapy in the treatment of non-small cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 6, 2000, Pages 1131-1161

  Sekine, Ikuo ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Combination chemotherapy; Non small cell lung cancer; Platinum

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ANIMAL; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; REVIEW;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 0034279239     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.6.1131     Document Type: Article

References (338)

1. PARKIN DM, PISANI P, FERLAY J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int.J. G7HO?r(1993) 54(4)094-606.
2. MAGRATH I, LITVAK J: Cancer in developing countries: opportunity and challenge. J. A"«/J. Cancer Inst. (1993) 85(10:862-874.
3. PISANI P, PARKIN DM, FERLAY J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int.J. Cancer (.1995) 55(6):891-903.
4. VALANIS BG: Epidemiology of lung cancer: a worldwide epidemic. Semin. Oncol. A'urs. (1996) 12(4):251-259.
5. STANLEY K, STJERNSWÄ RD J: Lung cancer - A worldwide health problem. C/j£>s/(1989) 96(7J:S1-S5.
6. HAMMAR SP: Common neoplasms. In: Pulmonary Patbolog)' - Tumours. Dail DH, Haramar SP, Colby TV (Eds.). Springer-Verlag, NY, USA (1995):1-156.
7. SEKINE I, KODAMA T, YOKOSE T et al.: Rare pulmonary tumors - a review of 32 cases. Oncology (1998) 55(5);431-434.
8. BAKOWSKI MT, CROUCH JC: Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat. Reviews (1983) 10(3):159-72.
9. JOHNSON DH: Chemotherapy for unresectable non-small cell lung cancer. Semin. Oncol. (1990) 17(4 Suppl. 7):20-29.
10. SEKINE I, KUBOTA K, NISHIWAKI Y, SASAKI Y, TAMURA T, SAIJO N: Response rate as an endpolnt for evaluating new cytotoxlc agents in Phase II trials of non-smallcell lung cancer. Ann. Oncol. (1998) 9OO):1079-1084.
11. LILENBAUM RC, GREEN MR: Novel chemotherapeutic agents in the treatment of non-small-ccll lung cancer. Clin. Oncol. (1993) 11(7):1391-1402.
12. BUNN PA Jr., KELLY K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. (1998) 4(5):1087-1100.
13. SOUQUET PJ, CHAUVIN F, BO1SSEL JP et al.: Polychcmotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet (1993) 342(8862):19-21.
14. GRILLI R, OXMAN AD, JULIAN JA: Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?/ Clin. O«coJ.(1993) 11(10,):1866-1872.
15. MARINO P, PA.MPALLONA S, PREATONI A, CANTONI A, INVERNIZZI F: Chemotherapy vs. supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest (1994) 106(3):86l-865.
16. SOUQUET PJ, CHAUjaN F, BOISSEL JP, BERNARD JP: Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lting Cancer (1995) 12(Suppl. l):S147-54.
17. NON-AMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med.J. (1995) 31K7010):S99-909.
18. MARINO P, PREATONI A, CANTONI A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages Ilia and Illb non-small cell lung cancer. A meta-analysis. Cancer (1995) 76(4)093-601.
19. PR1TCHARD RS, ANTHONY SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-ccll lung cancer. A meta-analysis. Ann. Intern. Med. (1996) 125(9):723-729.
20. GO RS, ADJEI AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin..J. Clin. Oncol. (1999) 17(0:409-422.
21. LOKICH J, ANDERSON N: Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol. (1998) 9U):13-21.
22. LOKICH J, ANDERSON N: Carboplatln versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol. (1998) 9(0:13-21.
23. BUNN PA: Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin. Oncol. (1992) 19 (1 Suppl. 2):1-11.
24. BONOMI PD, F1NKELSTEIN DM, RUCKDESCHEL JC et al: Combination chemotherapy versus single agents followed by combination chemotherapy In stage IV non-small-ccll lung cancer: a study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. (1989) 7(10:1602-613.
25. KLASTERSKY J, SOULIER JP, LACROIX H et al.: A randomized study comparing cisplatin or carboplatin with ctoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 0786l. J. Clin. Oncol. (1990) 8(9):1556-1562.
26. WANI MC, TAYLOR HL, WALL ME, COGGON P, MCPHAIL AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antilcukcmic and antitumor agent from Taxus brevifolia. J. Am. Chetn. Soc. (1971) 93(9):2325-2327.
27. GELFAND VI: Microtubule dynamics: mechanism, regulation and function. Ann. Rev. Cell Biol. (1991) 7:93-116.
28. DESAI A, MITCHISON TL: Microtubule polymerization dynamics. Ann. Rev. Cell Biol. (1997) 13:83-117
29. NISHIO K, SAIJO N: Cytoskeletons and antimitotic agents developed in Japan. Anticancer Dntg Design (1999) 14(0:133-141.
30. ROWINSKY RK. CAZENAVE LA, DONEHOWER RC: Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. (1990) 82(15)11247-1259.
31. MONZO M, ROSELL R, SANCHEZ JJ et al.: Paclitaxel resistance in non-small cell lung cancer associated with bcta-tunulin gene mutations./ Clin. Oncol. (1999) 17(6):1786-1793.
32. BELOTTI D, VERGANI V, DRUDIS T et al.: The microtubulc-affccting drug paclitaxcl has antiangiogcneic activity. Clin. Cancer Res. (1996) 2(11):1843-1849.
33. THATCHER N, RANSON M, ANDERSON H et al.: Phase III study of paclitaxcl (Taxol) (T) versus best supportive care (BSC) in inoperable non-small cell lung cancer (NSCLC). Ann. Oncol. (1998) 9(Suppl. 4):1.
34. CHOU TC, MOTZER RJ, TONG Y, BOSL GJ: Computerized quantitation of syncrgism and antagonism of taxol, topotccan and cisplatin against human tcratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. (1994) 86(20):1517-1524.
35. JEKUNEN AP, CHRISTEN RD, SHALINSKY DR, HOWELL SB: Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br.J. Cancer (1994) 69(2):299-306.
36. KANO Y, AKUTSU M, TSUNODA S, SUZUKI K, YAZAV7A Y: In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Cbemotber. Pharmacol. (1996) 37(6):525-530.
37. PARKER RJ, DABHOLKAR MD, LEE KB, BOSTICK-BRUTON F, REED E: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. Monogr. Nat!. Cancer Inst. (1993) 15(l):83-88.
38. ROWINSKY EK, CITARDI MJ, NOE DA, DONEHOWER RC: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubulc agents taxol and vincristine. J. Cancer Res. Clin. Oncol. (1993) 119(12):727-733.
39. UNTCH M, SEVIN BU, FERRAS JP et al.-. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxcl-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gyn. Oncol. (1994) 53(l):44-49.
40. VANHOEFER U, HARSTR1CK A, WILKE H et al.: Scheduledependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur.J. Cancer-(1995) 31A(l):92-97.
41. LEVASSEUR LM, GRECO WR, RUSTUM YM, SLOCUM HK: Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Cancer Cbemotber. Pharmacol. (1997) 40(6):495-505.
42. ZAFFARONI N, SILVESTRINI R, ORLAND1 L, BEARZATTO A, GORNATI D, VILLA R: Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatln-scnsitivc and -resistant human ovarian cells. Br.J. Cancer(1998) 77(9):1378-1385.
43. ROSE W'C: Taxol-based combination chemotherapy and other in vivo prcclinical antitumor studies. Monogr. Natl. Cancer Imt. (1993) 15(l):47-53.
44. MILROSS CG, PETERS LJ, HUNTER NR, MASON KA, MILAS L: Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo. Int. J. Cancer (1995) 62(5)099-604.
45. FUJIMOTO S, CHIKAZAWA H: Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murinc lung carcinoma in vivo. Jpn. J. Cancer Res. (1998) 89(12):1343-1351.
46. ROWINSKY EK, GILBERT MR, MCGUIRE WP et al.: Sequences of taxol and cisplatin: Phase I and pharmacologie study. J. Clin. Oncol. (1991) 9(9);1692-1703.
47. HOJO F, KAKINUMA R, OHE Y eta!.: Phase I and pharmacokinctic studies of paclitaxel with cisplatin in patients with non-small-ccll lung cancer. Proc.Am. Soc. Clin. Oncol. (1998) 17:488a.
48. KLASTERSKY J, SCULIER JP: Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. European Lung Cancer Working Party. Lung O?»cer(1995) 12(Suppl. 2):S117-25.
49. BELLI L, LECHEVALIER T, GOTTFRIED M et al.: Phase I/1I study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. Semin. Oncol. (1995) 22(6 Suppl. 15):29-33.
50. GEORGIADIS MS, SCHULER BS, BROUN JE et al.: Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a Phase I trial in patients with advanced lung cancer. J. Clin. Oncol. (1997) 15(2):735-743.
51. POSTMUS PE, GIACCONE G, DEBRUYNE C, SAHMOUD T, SPLINTER TA, VANZANDW1JK N: Results of the Phase II EORTC study comparing paclitaxel/cisplatin with teniposidc/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group. Semin. Oncol. (1996) 23(5 Suppl. 12):10-13.
52. VON PAWEL J, WAGNER H, NIEDERLE N et al.-. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin. Oncol. (1996) 23(6 Suppl. 16):47-50.
53. SORENSEN JB, WEDERVANG K, DOMBERNOWSKY P: Preliminary results of a Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin. Oncol. (1997) 24(4 Suppl. 12):S12-18-S12-20.
54. HSU JW, HSU JY, CHIANG CD: Preliminary result of Phase II study of paclitaxel and cisplatin chemotherapy for advanced non-small-cell lung cancer in Chinese patients. Am.J. Clin. Oncol. (1998) 21(5):487-490.
55. GATZEMEIER U, VON PAWEL J, GOTTFRIED M et al.: Phase III study of high-dose cisplatin (HD-cis) versus a combination of paclitaxel (TAX) and cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1998) 17:454a.
56. GIACCONE G, SPLINTER TA, DEBRUYNE C et al.: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol. (1998) 16(6):2133-2141.
57. BONOMI P, KIM K, FAIRCLOUGH D et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. (2000) 18(3):623-631.
58. HUIZING MT, GIACCONE G, VAN WAR.MERDAM LJC et ah. Pharmacokinctics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer. J. Clin. Oncol. (1997) 15(0:317-329.
59. OBSAJUCK, JOHNSON SW, ROGATKO A et al: Evaluation of carboplatin pharmacokinctics in the absence and presence of paclitaxel. Clin. Cancer Res. (1996) 2(3):549-552.
60. KELLY K, PAN Z, MURPHY J, HUFFMAN DH, BUNN PA, Jr.: A Phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin. Cancer Res. (1997) 3(7):1117-1123.
61. BELANI CP, KEARNS CM, ZUHOWSKI EG et al: Phase I trial, including pharmacokinctic and pharmacodynamic correlations, of combination paclitaxcl and carboplatin in patients with me t astatic non-small-cell lung cancer./ Clin. Oncol. (1999) 17(2):676-<584.
62. ROWINSKY EK, FLOOD WA, SARTORIUS SE, BOWLING KM, ETTINGER DS: Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Invest. New Dnigs (1997) 15(2):129-13S.
63. DUNPHY FR, BOYD JH, KIM HJ et al.: A Phase I report of paclitaxcl dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Cancer (1997) 79(10):20l6-2023.
64. SIDDIQUI N, BODDY AV, THOMAS HD et ah. A clinical and pharmacokinctic study of the combination of carboplatin and paclitaxcl for epithelial ovarian cancer. Br.J. Cancer (1997) 75(2):287-294.
65. NATALE RB: Preliminary results of a Phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol. (1996) 23(5 Suppl. 12):2-6.
66. GIACCONE G, HUIZING M, POSTMUS PE et al.: Dose-finding and sequencing study of paclitaxcl and carboplatin in non-small cell lung cancer. Semin. Oncol. (1995) 22(4 Suppl. 9):78-82.
67. BOOKMAN MA, MCGUIRE WP III, KILPATRICK D et al. Carboplatin and paclitaxel in ovarian carcinoma: Phase I study of the Gynecologic Oncology Group. Clin. Oncol. (1996) 14(6):1895-1902.
68. DE BOIS A, LÜ CK HJ, BAUKNECHT T et al.: Phase I/II study of the combination of carboplatin and paclitaxcl as first-line chemotfierapy in patients with advanced epithelial ovarian cancer. Ann. Oi;coJ.(1997) 8:355-361.
69. BELANI CP, NATALE RB, LEE JS et al.: Randomized Phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxcl in advanced and metastatic non-small cell lung cancer (NSCLC). Pmc.Ain.Soc. Clin. Oncol. (1998) 17:455a.
70. DU BOIS A, RICHTER B, WARM M et al.: Cisplatin/paclitaxel rs. carboplatin/paclitaxcl as Ist-line treatment in ovarian cancer. Proc.Am. Soc. Clin. Oncol. (1999) 18:36la
71. GATZEMEIER U, ROSELL R, BELTICHER D et al.: Randomized Pan-European trial comparing paclitaxcl/carboplatin versus paclitaxcl/cisplatin in advanced non-small cell lung cancer. Eur. J. Cancer (1999) 35(Suppl. 4):S246.
72. KOSMIDIS PA, MYLONAKIS N, SKARLOS D et al.: A multiccntcr randomized trial of paclitaxcl (175 mg/m2) plus carboplatin (6AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6AUC) in advanced non-small cell lung cancer (NSCLC). Pmc.Ain.Soc. Clin. Oncol. (1999) 18:463a
73. BISSERY MC, NOHYNEK G, SANDERINK GJ, LAVELLE F: Docetaxel (Taxotere): a review of prcclinical and clinical experience. Part I: prcclinical experience. Anticancer Dnigs (1995) 6(l):339-368.
74. CORTES JE, PAZDUR R: DocetaxeL / Clin. Oncol. (1995) 13(10):2643-2655.
75. DIAZJF.ANDREUJM: Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry and competition. Biochemist (1993) 32(11):2747-2755.
76. RINGEL I, HORWITZ SB: Studies with RP 56976 (Taxotere): a semisynthetic analogue of TaxoL J. Kail. Cancer bist. (1991) 83(4):288-291.
77. GUERITTE-VOEGELEIN F, GUENARD D, LAVELLE F, LE GOFF ME, MANGATAL L, POTIER P: Relationships between the structure of taxol analogues and their antimitotic activity./ Mod. Cbem. (1991) 34(3):992-998.
78. FROMES Y, GOUNON P, VEITIA R, BISSERY MC, FELLOUS A: Influence of microtubule-associated proteins on the differential effects of paclitaxcl and docctaxcl. J. rotein Cbem. (1996) 15(4):377-388.
79. ANDREU JM, DIAZ JF, GIL R et al.: Solution structure of Taxotcrc-induced microtubules to 3-nm resolution. Biol. Cbem. (1994) 269(50):31785-31792.
80. RIOU JF, PETIGENET O, CO.MBEAU C, LAVELLE F: CeUular uptake and efflux of docctaxel (Taxotere) and paclitaxcl (Taxol) in P388 cell line. Proc.Ann. Meet. Am. Assoc. CancerKes. (1994) 352292.
81. HALDAR S, BASU A, CROCE CM: Bcl2 is the guardian of microtubulc integrity. Cancer Res. (1997) 57(2):229-233.
82. HENNEQUIN C, GIOCANTI N, FAVAUDON V: S-phase specificity of cell killing by docctaxel (Taxotere) in synchronised HeLa cells. Br. J. Cancer (1995) 71(6):1194-1198.
83. KELLAND LR, ABEL G: Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Cbemotber. Pbannacol. (1992) 30(6):444-450.
84. VOGEL M, HILSENBECK SG, DEPENBROCK H et al.: Preclinical activity of Taxotere (RP 56976, NSC 628503) against freshly cxplanted clonogcnic human tumor cells: comparison with Taxol and conventional antineoplastic agents. Eur. J. Cancer (1993) 29A(14):2009-2014.
85. RIOU JF, NAUDIN A, LAVELLE F: Effects of Taxotere on murine and human tumor cell Unes. Biocbem. Biophys. Res. Commun. (1992) 187(l):l64-170.
86. UNTCH M, UNTCH A, SEVIN BU et al.: Comparison of paclitaxcl and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs (1994) 5(1):24-30.
87. HANAUSKE AR, DEGEN D, HILSENBECK SG, BISSERY MC, VON HOFF DD: Effects of Taxotere and taxol on in vitro colony formation of freshly explantcd human tumor cells. AnticancerDmgs(.1992) 3(2):121-124.
88. BISSERY MC, GUENAUD D, GUERITTE-VOEGELEIN F, LAVELLE F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. (1991) 51(18):4845-4852.
89. NICOLETT1 MI, LUCCHINI V, D'ICALCI M, GIAVAZZI R: Comparison of paclitaxcl and docetaxcl activity on human ovarian carcinoma xcnografts. Ear. J. Cancer (1994) 30A(5):691-696.
90. FOSSELLA FV, LEE JS, SHIN DM et al.: Phase II study of docetaxcl for advanced or mctastatic platinumrefractory non-small-cell lung cancer. J. Clin. OucoJ.(1995) 13(3):645-651.
91. ALEXOPOULOS K, KOUROUSSIS CANDEROULAKIS N et al.: Docetaxel and granulocyte colony-stimulating factor inpatients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multiccnter phase II trial. Cancer Chemother. Pbarmacol. (1999) 43(3):257-262.
92. NAKAMURA Y, KUNITOH H, AONO H et ah. A Phase U study of low-dose docetaxcl (DCT) 60 mg/m2 in platinum-prctreatcd advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1999) 18:518a.
93. GANDARA DR, YOKES E, GREEN M et al.: Activity of docetaxcl in platinum-treated non-small cell lung cancer: results of a Phase II multicenter trial. J. Clin. Oncol. (2000) 18(0:131-135.
94. SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy./ Clin. Oncol. (2000) 18(10):2095-2103.
95. FOSSELLA FV, DEVORE R, KERR R et a!.: Randomized Phase III trial of docetaxcl versus vinorelbinc or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinumcontaining chemotherapy regimens. J. Clin. Oncol. (2000) 18:2354-2362.
96. AOE K, KIURA K, UEOKA H eta!.: Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res. (1999) 19(lA):291-299-
97. ENGBLOM P, RANTANEN V, KULMALA J, HELENIUS H, GRENMAN S: Additive and supra-additivc cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br.J. Cancer (1999) 79(2):286-292.
98. BISSERY M-C, VRIGNAUD P, LAVELLE F: Preclinical profile of docetaxel (Taxotere): efficacy as a single agent and in combination. Semin. Oncol. (1995) 22(6 Suppl. 13):3-16.
99. BISSERY M-C, NOHYNEK G, SANDERRINK G-J, LAVELLE F: Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Res. (1995) 6(2):339-368.
100. CROWN J, FUMOLEAU P, KERBRAT P et ah. Phase I trial of docetaxel (D) with cisplatin (P) as first-line chemotherapy of mctastatic breast cancer (MBC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1997) l6:821a.
101. WATANABE K, HAYASHI I, HIRAKIS et ah. Phase I/II dose escalation study of docetaxel (TXT) and cisplatin (CDDP) for stage IV non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1997) I6:899a.
102. PRONK LC, SCHELLENS JH, PLANTING AS ct al: Phase I and pharmacologie study of docctaxel and cisplatin in patients with advanced solid tumors./ Gin. Oncol. (1997) 15(3):1071-1079.
103. MILLWARDMJ, ZALCBERG J, BISHOP JF eta!.-. Phasel trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (1997) 15(2):750-758.
104. COLE JT, GRALLA RJ, MARQUES CB, RITTENBERG CN: Phase Ml study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1995) l4:1087a.
105. LE CHEVALIER T, MONNIER A, DOUILLARD JY et al.-. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur. J. Cancer (1998) 34(13):2032-2036.
106. GEORGOULIAS Y, ANDROULAKIS N, DIMOPOULOS AM et al.: First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter Phase II study. Ann. Oncol. (1998) 9(3):331-334.
107. ZALCBERG J, MILLWARD M, BISHOP J etal.: Phase U study of docetaxel and cisplatin in advanced non-small-ccll lung cancer. / Clin. Oncol. (1998) 16(5):1948-1953.
108. BELANI CP, BONOMI P, DOBBS T et a!.: Multicenter Phase U trial of docetaxel and cisplatin combination in patients with non-small cell lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1997) I6:l660a.
109. WATANABE K, HAYASHI I, SEGAWA Y, ct al.: Phase I/II study of docetaxel (TXT) and cisplatin (CDDP) in patients with previously untreated . mctastatic non-small cell lung cancer (NSCLC). Ann. Oncol. (1998) 9(Suppl. 4):91.
110. GEORGOULIAS V, PAPADAKIS E, ALEXOPOULOS A etal: Docetaxel plus cisplatin versus docetaxel plus gcmcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of a multicenter randomized Phase II triaL Proc. Am. Soc. Clin. Oncol. (1999) 18:46la
111. SCHILLER JH, HARRINGTON D, SANDLER A et al.: A randomized Phase III trial of four chemotherapy regimens in advanced non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:la.
112. TAKEDA K, YAMAMOTO N, NEGORO S et al.: Randomized Phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotccan in advanced non-small-cell lung cancer (NSCLC): a West Japan Thoracic Oncology Group (WJTOG) study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:497a.
113. BELANI CP, HADEED V, RAMANATHAN R etal.: Docetaxel and carboplatin: a phase I and pharmacokinetic trial for advanced non-hcmatologic malignancies. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1997) I6:771a.
114. LANGER C, MCALEER C, MILLENSON M Ct a!.: Phase I evaluation of docetaxel (D) and carboplatin (C) in advanced malignancies: stratification of patient cohorts based on prior treatment (TX) status yields useful results. Proc. Anna. Meet. Am. Soc. Clin. Oncol. (1998) 17:204a.
115. CAPOSSOLI MJ, BELAN1 CP, EINZIG A et al.-. Multiinstitutional Phase II trial of docetaxel and carboplatin combination in patients (PTS) with stage IIIB and IV non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:479a.
116. POTIER P: The synthesis of Navelbine® prototype of a new series of vinblastine derivatives. Semin. Oncol. (1989) 16(2 Suppl. 4):2-4.
117. BUDNAN DR. Vinorelbine (Navelbine): a thirdgeneration vinca alkaloid. Cancer Invest. (1997) 15(5):475-490.
118. BINET S, FELLOUS A, LATASTE H, KRIKORIAN A, COUZINIER JP, MEININGER V: In situ analysis of the action of Navelbine® on various types of microtubules using immunofluorescence. Semin. Oncol. (1989) 16(2 Suppl. 4):5-8.
119. FELLOUS A, OHAYON R, VACASSIN T et ah. Biochemical effects of Navelbine® on tubulin and associated proteins. Semin. Oncol. (1989) 16(2 Suppl. 4):9-l4.
120. THE ELDERLY LUNG CANCER VINORELBINE ITALIAN STUDY GROUP: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbinc Italian Study Group. / Katl. Cancer last. (1999) 9KD:66-72.
121. FURUSE K, FUKUOKA M, KUBA M et al.: Randomized study of vinorelbinc (VRB) versus vindesine (VDS) in previously untreated stage IIIB or TV non-small-cell lung cancer (NSCLCl The Japan Vinorelbine Lung Cancer Cooperative Study Group. Ann. Oncol. (1996) 7(8):815-820.
122. CRAWFORDJ, O'ROURKEM, SCHILLERJH etal.-. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-smallcell lung cancer. J. Clin. Oncol. (1996) l4(10):2774-2784.
123. ELLIOTT JA, AHMEDZAI S, HOLE D et ai: Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Enr.J. Cancer Clin. Oncol. (1984) 20(8):1025-1032.
124. KRIS MG, GRALLA RJ, KALNIAN LA etal.: Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat. Rep. (1985) <59(4):387-395.
125. DHINGRA JM, VALDIVIESO M, CARR DT et al.: Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. (1985) 3(2):176-183.
126. PACCAGNELLA A, BRANDES A, PAPPAGALLO GL et al: Cisplatin plus vindesine versus cisplatin plus VP16 versus doxorubicin plus cytoxan in non-small-cell carcinoma of the lung. A randomized study. Tiimoim (1986) 72(4):4l7-425.
127. EINHORN LH, LOEHRER PJ, WILLIAMS SD et al: Random prospective study of vindcsine versus vindcsine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer./ Clin. Oticol. (1986) 4(7):1037-1043.
128. RUCKDESCHEL JC, FINKELSTEIN DM, ETTINGER DS et al.: A randomized trial of the four most active regimens for me tas ta tic non-small-ccll lung cancer. J. Clin. Oncol. (1986) 4(l):l4-22.
129. RAPP E, PATER JL, WILAN A et a!.: Chemotherapy can prolong survival in patients with advanced non-small-ccll lung cancer - report of a Canadian multiccntcr randomized trial. J. Clin. Oncol. (1988) 600:633-641.
130. WOODS RL, \\1LLWAMS CJ, LEVI J et ah. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br. J. Ca;icer(1990) 6l(4):60S-6ll.
131. KAWAHARA M, FURUSE K, KODAMA N et al.-. A randomized study of cisplatin versus cisplatin plus vindcsine for non-small cell lung carcinoma. Cancer (1991) 68(4):714-719.
132. FUKUOKAM, MASUDA N, FURUSE K et al.: A randomized trial in inoperable non-small-ccll lung cancer: vindcsine and cisplatin I'ersus mitomycin, vindcsine and cisplatin versus etoposide and cisplatin alternating with vindcsine and mitomycin. J. Clin. Oncol. (1991) 9(4):606-613.
133. CROS S, WRIGHT M, MORIMOTO M, LATASTE H, COUZINIER JP, KRIKORIAN A: Experimental antitumor activity of navelbine. Semin. Oncol. (1989) 16(2 Suppl. 4): 15-20.
134. GOMI K, OHNO H, NOMURA K, OKABE M, KOBAYASHI K, NIITANI H: Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adcnocarcinoma PC-12 cells in culture. Jap. J. Cancer Res. (1992) 83(5):532-539.
135. ASHIZAWA T, ASADA M, KOBAYASHI E, OKABE M, GOMI K, HIRATA T: Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia« and human lung carcinoma xcnografts in mice. Anticancer Drugs (1993) 4(5):577-583.
136. ROUSSAKIS C, POUCHUS YF, GRATAS C et al.: In vivo study of vinorclbinc associations with cisplatin, 5-fluorouracil or actinomycin D relative to a non-small-cell lung carcinoma (NSCLCN6-L16). Anticancer Dmg DCS. (1993) 8(2):l65-171.
137. BERTHAUD P, LE CHEVALIER T, RUFFIE P et al.: Phase HI study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Enr. J. Cancer (1992) 28A(11):1S63-1S65.
138. BRETTI S, BERRUTI A, GORZEGNO G et ah Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients. Lung Cflucer(1996) l4(2-3):353-360.
139. ADAM Z, COUPKOVA H, KOLEK V et ah Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: results of a multiccntcr Czech study. Acta Med. Austria. (1995) 22(5):120-124.
140. GEBBIA V, CARUSO M, VALENZA R et al.: Vinorclbine plus cisplatinutn for the treatment of stage IIIB and IV non small cell lung carcinoma. Anticancer Res. (1994) 14(3B):1247-1249.
141. BROOKS BJ, GRALLA RJ, MCGAW HJ, OTTEN MC, LANG AC, RITTENBERG CN: Cisplatin + vinorelbine (Navelbine) combination chemotherapy for advanced non-small cell lung cancer: testing the efficacy of a regimen designed to reduce toxicity and increase dose-intensity. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1994) 13:ll62a.
142. DEPIERRE A, CHASTANG C, QUOIX E et al.: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized triaL Ann. Oncol. (1994) 5(0:37-42.
143. LE CHEVALIER T, BRISGAND D, DOUILLARD JY et a!.: Randomized study of vinorelbine and cisplatin versus vindcsine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multiccnter trial including 612 patients. J. Clin. Oncol. (1994) 12(2):3öO-3ö7.
144. WOZNIAK AJ, CROWLEY JJ, BALCERZAK SP et al.-. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-ccll lung cancer: a Southwest Oncology Group study./ Clin. Oncol. (1998) l6(7):2459-2465.
145. MARTON1 A, GUARALDI M, PIANA E et al.: Multicenter randomized clinical trial on high-dose cpirubicin plus cis-platinum versus vinorclbinc plus els-platinum in advanced non small cell lung cancer. Lung Cancer (1998) 22(l):31-38.
146. GEBBIA V, GALATTA D, RICCARDI F et al.: Mitomycin plus vindesine and cisplatin (MVP) versus vinorelbine and cisplatin (PV) in stage III-IV non-small cell lung cancer: a randomized Phase III trial of the Southern Italy Oncology Group Study (G.O.I.M.). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:465a
147. COLLEONI M, BONI L, VICARIÖ G étal: A dose-escalating study of carboplatin combined with vinorelbine in non-small-ccll lung cancer. Oncology (1996) 53(5):364-368.
148. JACOULET P, BRETON JL, WESTEEL V, MERCIER M, GARNIER G, DEPIERRE A: Phase I study of Vinorclbine and carboplatin in advanced non-small cell lung cancer. Lung Cai!C
149. CRANVFOLD J, O'ROURKE MA, HERNDOXJ, JOHNEKERJ, BURMAN S: Sequential trials of vinorelbine (navelbine, NVB) with carboplatin in patients with advanced non small cell lung cancer (NSCLC). Proc. Ann. Meet. A in. Soc. Clin. Oncol. (1995) 14:1 l62a.
150. SANTOMAGGIO C, TUCCI E, RINALDINI M et al.: Carboplatin and vinorclbinc in the treatment of advanced non-small-cell lung cancer: a multiccntcr Phase II study. Am.]. Clin. Oncol. (1998) 21(1):67-71.
151. PRONZATO P, GHIO E, LOSARDO PL, LANDUCCI M, VAIRA F, VIGANI A: Carboplatin and vinorelbine in advanced non-small-ccll lung cancer. Cancer Cbemothera. Pbannacol. (1996) 37(6):6lO-6l2.
152. GARST J, CRAWFORD J, O'ROURKE O et al.: Vinorelbine (NVB) and carboplatin (C) for the treatment of patients with advanced non-small cell lung cancer (NSCLC): a Phase II response, toxicity and survival study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1996) 15:1233a.
153. MASOTTIA, BORZELLINO G, ZANNINI G, LATERZA E, RICCI F, MORANDINI G: Efficacy and toxicity of vinorelbine-carboplatin combination in the treatment of advanced adenocarcinoma or large-cell carcinoma of the lung. Tnmoiiri. (1995) 81(2):112-116.
154. BALDINI E, TIBALDI C, ARDIZZONI A et al: Cisplatinvindesine-mitomycin (MVP) vs. cisplatin-ifosfamidevinorelbine (PIN) vs. carboplatin-vinorclbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized Phase II study. Italian Lung Cancer Task Force (FONICAP). Br.J. Cïwcer(1998) 77(12):2367-2370.
155. PERIGAUD C, GOSSELIN G, IMBACH J: Nucleoside analogues as chemotherapeutic agents: a review. Kitcleosides Kucleotldes (1992) ll(2-4):903-945.
156. HERTEL WL, KROIN JS, MISNER JW, TUSIN JM: Synthesis of 2-deoxy-2, 2-difluoro-D-ribose and 2-deoxy-2, 2-D-ribofuranosyl nuclcosides. J. Org. Chem. (1988) 53(11):2406-2409.
157. BOUFFARD DY, MOMPARLER LF, MOMPARLER RL: Comparison of antincoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinosidc against human mycloid and lymphoid Icufccmic cells. Anticancer Drugs (1991) 2(l):49-55.
158. HERTEL LW, BODER GB, KROIN JS et al.-. Evaluation of the antitumor activity of gcmcitabine (2',2-difluoro2'-deoxycytidine), Cancer Res. (1990) 50(14):4417-4422.
159. GUCHELAAR HJ, RICHEL DK, VAN KNAPEN A: Clinical, toxicological and pharmacological aspects of gcmcitabine. Cancer Treat. Rev. (1996) 22(0:15-31.
160. PLUNKETT W, HUANG P, XU YZ, HEINEMANN V, GKUNFAVALD R, GANDHI V: Gemcitabine: metabolism, mechanisms of action and sclf-potentiation. Semin. Oncol. (1995) 22(4 Suppl. 11):3-10.
161. ANDERSON N, COTTIER B, NICOLSON M et al.: Phase III study of gcmcitabine (Gemzar) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung CoHcer(1997) 18(Suppl. 1):9.
162. MANEGOLD C, BERGMAN B, CHAMAISSANI A et al.: Single-agent gcmcitabine versus cisplatin-ctoposide: early results of a randomised Phase II study in locally advanced or mctastatic non-small-ccll lung cancer. Ann. Oncol. (1997) 8(6)025-529.
163. TEN BOKKEL HUININK WW, BERGMAN B, CHEMAISSANI A et al.-. Single-agent gcmcitabine: an active and better tolerated alternative to standard cisplatin-bascd chemotherapy in locally advanced or mctastatic non-small cell lung cancer. Lung Cancer (1999) 26(2):85-94.
164. PERNG RP, CHEN YM, MING-LIU J et al.: Gcmcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a Phase II randomized study. J. Clin. Oncol. (1997) 15(5):2097-2102.
165. CRINO L, MOSCONI Ml, SCAGL1OTTI G et al.: Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a Phase U trial J. Clin. Oncol. (1999) I7C7):2081-2085.
166. ROSVOLD E, LAKGER CJ, SCHILDER R et al.: Salvage therapy with gcmcitabinc in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel (C-P). I'roc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:467a.
167. GARFIELD DH, DAKH1L SR. WHITTAKER TL et al.: Phase U randomized multiccntcr trial of two dose schedules of gcmcitabinc as second-line therapy in patients with advanced non-small cell lung cancer (ANSCLC). Pmc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:4&4a.
168. ROCCI A, PERRONE F, BARLETTA E et al.: Activity of gemcitabinc (GEM) in cisplatin-pretreated patients with advanced non-small cell lung cancer (NSCLC): a Phase 2 trial. Pmc. Ann.Meet. Am. Soc. Clin. Oncol. (1999) 18:484a.
169. VAN MOORSEL CJ, PINEDO HM, VEERMAN G, VERMORKEN J15, POSTMUS PE, PETERS GJ: Scheduling of gcmcitabinc and cisplatin in Lewis lung tumour bearing mice. Eur.J. Cancer W))) 35(5):80S-8l4.
170. PADRON JM, VAN MOORSEL CJ, BERGMAN AM, SMITSKAMP-WILMS W, VAN DER WILT CL, PETERS GJ: Selective cell kill of the combination of gcmcitabinc and cisplatin in multijayered postconflucnt tumor cell cultures. Anticanccr Drugs (1999) 10(5):445-452.
171. BERGMAN AM, RUIZ VAN HAPEREN VW, VEERMAN G, KUIPER CM, PETERS GJ: Syncrgistic interaction between cisplatin and gcmcitabinc tit vitro. Clin. Cancer Res. (1996) 2(3):521-530.
172. BRAAKHUIS BJ, RUIZ VAN HAPEREN VW, WELTERS MJ, PETERS GJ: Schedule-dependent therapeutic efficacy of the combination of gerne itahine and cisplatin in head and neck cancer xenografts. Eur. J. Cancer (1995) 31A(13-14):2335-2340.
173. PETERS GJ, BERGMAN AM, RUIZ VAN HAPEREN VW, VEERMAN G, KUIPER CM, BRAAKHUIS BJ: Interaction between cisplatin and gcmcitabinc in vitro and in vivo. Semin. Oncol. (1995) 22(4 Suppl. ll):72-79.
174. VAN MOORSEL CJ, PINEDO HM, VEERMAN G et al.: Mechanisms of synergism between cisplatin and gcmcitabine in ovarian and non-small-cell lung cancer cell lines. Br.J. Cancer(1999) 80(7):981-990.
175. CARTEI G, SACCO C, SIBAU A, PELLA N, IOP A, TABARO G: Cisplatin and gcmcitabinc in non-small-ccll lung cancer. Ann. Oncol. (1999) lOCSuppl. 5):S57-62.
176. ABRATT RP, SANDLER A, CRINO L et al.-. Combined cisplatin and gcmcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. 5
177. RICCI S, ANTONUZZO A, GALLI L et al.-. Combination chemotherapy with two different schedules of gemcitabine (GEM) plus cisplatin (CDDP) in patients with stage IIIB-IV NSCLC: a multicentric randomized Phase II study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18-A8Q3
178. PARRA HJS, CAVINA R, ANTONELLIG étal.: Superiority of three-week rs. four-week schedule of cisplatin (CDDP) and gemcitabine (GEM): results of a randomized Phase II study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:546a
179. SANDLER AB, NEMUNAITIS J, DENHAM C et al.-. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or mctastatic non-small cell lung cancer. J. Clin. Oncol. (2000) 18:122-130.
180. CARDENAL F, LOPEZ-CABRERIZO MP, ANTON A et al.-. Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or mctastatic non-small-cell lung cancer. J. Clin. Oncol. (1999) 17(1):12-18.
181. CRINO L, CONTE P, DEMARINIS F et al.: A randomized trial of gemcitabine cisplatin (GP) versus mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC). A multiccnter Phase III study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:455a.
182. LANGER CJ, GANDARA DR, CALVERT P, EDELMAN MJ, OZOLS RF: Gemcitabine and carboplatin in combination: an update of Phase I and Phase II studies hi non-small cell lung cancer. Semin. Oncol. (1999) 26(1 Suppl. 4):12-18.
183. TAKIMOTO CH, KIEFFER LV, ARBUCK SG: DNA topoisomerase I inhibitors. Cancer Cbemother. Biol. Response Modifiers W)7) 17:80-113.
184. NITISS JL: Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochem. liiophy's. Acta(1998) l400u-3):63-81.
185. MASUDA N, KUDOH S, FUKUOKA M: Irinotecan (CPT-11): pharmacology and clinical applications. Crit. Rev. Oncol. Hematol. (1996) 24(l):3-26.
186. MINAGAWA Y, KIGAWA J, ISHIHARA H, ITAMOCHI H, TERAKAWA H: Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-rcsistant HeLa cells. Jpn. J. Cancer Res. (1994) 85(9):966-971.
187. KUDOH S, TAKADA M, MASUDA N et al.: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin and cisplatin against human lung tumor xcnografts.Jpn.J. Cancer Res. (1993) 84(2):203-207.
188. KANO Y, SUZUKI K, AKKUTSU M et al.: Effects of CPT-11 in combination with other anti-cancer agents in culture. Int.J. Cancer(1992) 50(4):604-6lO.
189. MASUDA N, FUKUOKA M, TAKADA M et al.: CPT-11 in combination with cisplatin for advanced non-smallcell lung cancer J CH». Oncol. (1992) 10(11):1775-1780.
190. SALTZ LB, SPRIGGS D, SCHAAF LJ et al.: Phase I clinical and pharmacologie study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J. Clin. Oncol. (1998) l6(12):3858-3865.
191. UEOKA H, TABATA M, KIURA K et ah. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a Phase I study. Br.J. Cancer (1999) 79(5-<5):9S4-990.
192. DE JONGE MJ, SPARREBOOM A, PLANTING AS et al.: Phase I study of 3-weck schedule of irinotecan combined with cisplatin in patients with advanced solid tumors J Clin. Oncol. (2000) 18(1): 187-194.
193. DE JONGE MJ, VERWEIJ J, PLANTING AS et al.: Drug-administration sequence docs not change pharmacodynamics and kinetics of irinotecan and cisplatin. din. Cancer Res. (1999) 5(8):2012-2017.
194. DE JONGE MJA, CERWEIJ J, DE BRUIJN P et ah. Pharmacokinctic, metabolic and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin J din. Oncol. (2000) 18(1):195-203.
195. MASUDA N, FUKUOKA M, FUJITA A et ah A Phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br.J. Cancer(.1998) 78(2):251-256.
196. DE VORE R, CRAWFORD J, DIMERY I et al.: Phase II trial of irinotecan (CPT-11) plus cisplatin (CDDP) in advanced NSCLC. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1997) I6:l67-1a.
197. MORI K, MACHIDA S, YOSHIDA T, KANO Y, TO.MINAGA K: A Phase II study of Irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-ccll lung cancer. Cancer Cbemotber. Pharmacol (1999) 43(6):467-470.
198. NIHO S, NAGAO K, NISHIWAKI Y et al: Randomized multicentcr Phase HI trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (YDS) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:492a.
199. MASUDA N, FUKUOKA M, NEGORO S et al.: Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicentcr phase III study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:459a.
200. FUKUOKA M, NAGAO K, OHASHI Y et al.: Impact of ' irinotecan (CPT-11) and cisplatin (CDDP) on survival in previously untreated matastatic non-small cell lung cancer (NSCLC). Pmc. Ann. Meet. Ain. Soc. Clin. Oncol. (2000) 19:495a
201. KAKOLYR1S S, ANDROULAKIS N, AGELAKIS et al.-. Salvage treatment of taxane-refractory advanced non-smallccll lung cancer (NSCLC) with a cisplatin plus irinotecan (CPT-11) combination. Proc. Ann. Meet. Am. Soc. Clin. Oi!coJ.(2000) 19:539a.
202. SHINKAI T, EGUCHI K, SASAKI Y et al: A randomised clinical trial of vindcsine plus cisplatiii versus mitomycin plus vindesinc and cisplatin in advanced non-small cell lung cancer. Etir. J. Cancer (1991) 27(5):571-575-
203. EINHORN LH, LOEHRER PJ, WILLIAMS SD et al: Random prospective study of vindesine versus vindcsine plus high-dose cisplatin versus vindcsine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer J Clin. Oncol. (1986) 4(7):1037-10-B.
204. BONOMI PD, FINKELSTEIN DM, RUCKDESCHEL JC et al.-. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. (1989) 7(11):I602-1613.
205. KOSMIDIS P, BEER M, MYLONAKIS N et al.-. Cisplatin/vinblastine (VP) vs. cisplatin/vinblastine ifosfamidc (VIP) in non-small cell lung cancer (NSCLC). A prospective randomized Phase III study. Pmc. Ann. Meet. Am. Soc. Clin. Oncol. (1992) ll:955a.
206. MASUTANI M, AKUSAWA H, KODOTA A et a!.: A Phase UI randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindcsine plus ifosfamide for advanced non-small-cell lung cancer. Kespirology (1996) l(l):49-54.
207. RUCKDESCHEL JC, FINKELSTEIN DM, ETTINGER DS et al.: A randomized trial of the four most active regimens for mctastatic non-small-cell lung cancer. J. Clin. Oncol. (1986) 4(l):l4-22.
208. DHINGRA HM, VALDIVIESO M, CARR DT et al.: Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. (1985) 3(2):176-183.
209. CRINO L, TONATO M, DARWISH S et al.-. A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Cbemotber. Pbnnnacol (1990) 26(1)02-56.
210. WEICK JK, CROWLEY J, NATALE RB et al.-. A randomized trial of five cisplatin-containing treatments in patients with mctastatic non-small-cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. (1991) 9(7):1157-1162.
211. FUKUOKA M, MASUDA N, FURUSE K et ah A randomized trial in inoperable non-small-ccll lung cancer: vindesine and cisplatin versus mitomycin, vindcsine, and cisplatin versus etoposidc and cisplatin alternating with vindesine and mitomycin. J. Clin. Oncol. (1991) 9(4);606-613.
212. ZANIBONI A, MERIGGI F, RIZZIA etal: PacUtaxel, ifosfamidc and carboplatin for the treatment of stages II1B and IV non-small cell lung cancer: preliminary results. Semin. Oncol. (1997) 24(4 Suppl. 12):S12-70-S12-72.
213. ANSARI RH, MAUER A, HUFFMAN PC et al.: A University of Chicago Consorium phase 2 study for non-small cell lung (NSCLC) cancer IIIB or IV disease with carboplatin, ifosfamidc (IFEX), paclitaxel and filgrastim support-8545. Proc. Anna. Meet. A m. Soc. Clin. Oncol. (1999) 18:494a
214. KOSMAS C, TSAVAR1S N, POLYZOS A et al.-. A Phase U study of paclitaxel (T)-ifosfamide (I)-cisplatin (P) (TIP) chemotherapy (CMT) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:512a
215. ZANIBONI A, DE MARINIS F, ARD1ZZONI A et al: Taxol (T), ifosfamidc (I) and carboplatin (C) is an active combination for stage IIIB-IV non-small-cell lung cancer (NSCLC). A multicenter validation study. Proc. Ann. Meet. Am. Soc. Clin. Oncol, (2000) 19;528a.
216. BREAU JL, PIPERKO-NEUMANN S, BOU1LLET T, COULON MA, MORERE JF: Cisplatin etoposide vinorelbine in advanced non-small cell lung cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (1997) l6:463a
217. MARANGOLO M: Vinorelbine (VB) + cisplatin (DDP) + etoposide (E) in the treatment of non-small cell lung cancer (NSCLC). Enr.J. CflHcer(1993) 29A(Suppl. 6):S163.
218. TAN EH, ANG PT, WEE J, FONG KW, LEON'G SS, KHOO KS: Vinorelbine, ifosfamidc and cisplatin in advanced non-small cell lung cancer. Ada Oncol. (1999) 38(5):6l9-622.
219. REY F, ASTOUL P, MARQUESTE L, PETITE JM, BOUTIN C, V1ALLAT JR: Cisplatin, ifosfamide and vinorelbine combination chemotherapy in stage I1I-IV non-smallcell lung cancer: a Phase II study. Am.J. Clin. Oncol. (1998) 21(5)018-522.
220. BALDINI E, TIBALDI C, CHELLA A et al.: Phase II study of vinorelbine/ifosfamicjp/cisplatin for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. (1996) 7(7):747-749.
221. MONTALAR J, YUSTE A, MORALES S et al: Vinorelbine, ifosfamide and cisplatin regimen in inoperable non small cell lung cancer patients. Enr. J. Cancer (1999) 35(SuppI. 4):S264.
222. RECCHIA F, DE FILIPPIS S, LOCOCO A et ah. Phase II study of navelbine (NVB), ifosfamide (IFO) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol (1996) 15:371
223. HEJNA M, KORNEK GV, RADERER M et al: Mitomycin C, vinorelbine, carboplatin plus granulocytemacrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma. Oncology (1998) 55(6)038-542.
224. FURUSE K, KAWAHARA M, NISHIWAKI Y et al: Phase I-II study of vinorelbine, mitomycin and cisplatin for stage IIIB or IV non-small cell lung cancer. J. Clin. Oncol. (1999) 17(10):3195-3200.
225. BONI C, BISAGNI G, SAVOLDI L et al: Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of stage IIIB-IV non-small cell lung cancer (NSCLC). A phase II study of the Italian Oncology Group for Clinical Research. Proc. Ann. Meet. Am. Soc. Clin. Oncol (1998) 17:478a
226. MARINI G, FERRARI VD, MARPICATI P et al.: gemcitabine (GEM) in combination with ifosfaniidc (IFO) and cisplatin (CDDP) in advanced non-small cell lung cancer (NSCLC): a Phase II study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:5l6a
227. NADAL CV, ALIGUER MN, MAYOL XF, GRAU ES, CASTILLO MG: A Phase II trial of the combination of gemcitabine, ifosfaniidc and cisplatin in the treatment of advanced non-small cell lung cancer. Lung Cancer (2000) 28(2):109-115.
228. PEROL M, GUERIN JC, THOMAS P et al.: Multicenter randomized trial comparing cisplatin-mitomycinvinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Francais de Pneumo-Cancerologie'. lung Cfl>ic
229. KAWAHARA M, FURUSE K, N1SHIWAKI Y el at.: Randomized study of vinorelbine (VKB) or vindesine (VDS) with cisplatin (C) and mitomycin (M) as induction chemotherapy in stage IIIB or IV non-small cell lung cancer (NSCLC) - final results. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:489a.
230. ADAMS DJ: Synergistic of navelbinc-taxol combination treatment in two human breast cancer cell lines. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1994) 35:327.
231. KANO Y, AKUTSU M, SUZUKI K, ANDO J, TSUNODA S: Schedule-dependent interactions between vinorelbine and paclitaxcl in human carcinoma cell Unes in vitro. Breast CancerKes. Treat. (1999) 56(1):79-90.
232. CULINE S, ROCH I, PINGUET F, ROMIEU G, BRESSOLLE F: Combination paclitaxcl and vinorclbinc therapy: in ritro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. J;;; J Oncol. (1999) 14(5):999-1006.
233. KNICK VC, EBERWEIN DJ, MILLER CG: Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vil'O P388 murinc leukemia cells. J. Katl. Cancer Inst. (1995) 87(14):1072-1077.
234. PAR1MOO D, JEFFERS S, MUGGIA FM: Severe neurotoxicity from vinorelbine-paclitaxcl combinations. J tiatl. Cancer Inst. (1996) 88(15):1079-1080.
235. IBRAHIM N, HORTOBAGYI GN, VALERO V et al.: Phase I study of vinorelbine (NVB; Navelbine) and paclitaxel (PTX) by simultaneous (sim) 3-hr infusion (inf) for untreated mctastatic breast cancer (MBC). Proc. Ann. Meet. Am. Assoc. Cancer Res. (1995) 36:1443.
236. IAFFAIOLI RV, TORTORIELLO GFA, ILLIANO FCA et al.: Phase I study of vinorelbine and paclitaxel in smallcell lung cancer. Cancer Chemotber. Pbarmacol. (1997J 4l(l):86-90.
237. CULINE S, ROCH I, PINGUET F, ROMIEU G, BRESSOLLE F: Combination paclitaxel and vinorclbinc therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. Int.J. Oncol. (1999) 14(5):999-1006.
238. BUDNAN DR, WEISELBERG L, O'MARA V et al.: A Phase I study of sequential vinorelbine followed by paclitaxcl. Ann. Oncol. (1999) 10(7):86l-863.
239. GRUNBERG SM, GREENBLATT M, OSPINA O eta!.: Phase I study of paclitaxel/vinorelbine (P/V) for advanced non-small cell lung cancer (NSCLC). Proc. Aniiti. Meet. Am. Soc. Cliu. Oncol. (1999) 18:507a
240. FEREZ JE, MACHIAVELLI MR, ROMERO AO et al: Vinorelbinc and paclitaxel for locorcgional advanced or me tastat ic non-small cell lung cancer (NSCLC). Proc. Anmi. Meet. Am. Soc. Clin. Oncol. (1999) 18:519a
241. CHANG A, DEVORE R, GU C, JOHNSON D, KENG P, ASBURY R: Paclitaxel (P) and vinorelbine (V) combination in advanced non-small cell lung cancer (NSCLC); in vitro and clinical studies. Proc. Ann. Meet. Am. Assoc. Cancer Kes. (1996) 37;1158a.
242. MASTERS GA, MAUER AM, HOFFMAN PC et al.: A Phase I-II study of paclitaxel, ifosfaniidc and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer. Ann. Oncol. (1998) 9(6):677-<580.
243. FRIEDNAN EL, STRAUS MJ, AMBINDER JM et al.: Vinorelbine, paclitaxel and carboplatin (VPC) for adcnocarcinoma of the lung. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:512a
244. THOMPSON DS, HAINSWORTH JD, HOPKINS LG et al.: Phase I study of vinorelbine, paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:5033
245. GRIMALDI M, HAINSWORTH JD, BUTTS JA et al.: Paclitaxel, carboplatin and vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase II trial of the Minnie Pearl Cancer Research Network. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:507a
246. THEODOSSIOU C, COOK JA, FISHER J et a!.-. Interaction of gcmcitabinc with paclitaxel and cisplatin in human tumor cell lines. Int.J. Oncol. (1998) 12(4):825-832.
247. EINHORN LH, RAGHAVAN D, KINDLER H et al.: A Pliase I study of gcmcitabinc plus paclitaxel combination therapy in patients with refractory solid tumors. Pme. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:207a
248. POOLE CJ, PERREN T, HOGBERG T et al.: Phase I study to investigate the optimal dose and schedule of gcmcitabinc (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:357a
249. ROTHENBERG ML, SHARMA A, WEISS GR et al.: Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann. Oncol. (1998) 9(7):733-738.
250. DE PAS TM, DANESI R, SESSA C et al.: Phase I study of gcmcitabinc (GEM) and paclitaxel (TAX) in chemonaivc patients with advanced non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol.aoOO) 19:532a.
251. ROTHENBERG ML, SHARMA A, WEISS GR et at.: Phase I trial of paclitaxel and gcmcitabinc administered eventwo weeks in patients with refractory solid tumors. Ann. Oncol. (1998; 9(7):733-738.
252. GIACCONE G, SMIT E, LAAN D et al.-. Phase I/II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC). Pmc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:486a
253. ANDROULAKIS N, KOUROUSSIS C, KAKOLYRIS S et al: Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter Phase II study. Ann. Oncol. (1998) 9(10):1127-1130.
254. KOSMIDIS PA, BACOYIANNIS N, MYLONAKIS N et al.: A randomized Phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non-small-ccll lung cancer (NSCLC): a preliminary analysis. Pmc. Ann. Meet. Ain. Soc. Clin. Oncol. (2000) 19:488a.
255. FRASCI G, PANZA N, COMELLA P et al.: Cisplatin, gemcitabine and paclitaxel in locally advanced or mctastatic non-small cell lung cancer: a Phase I/II study J Clin. Oncol. (1999) 17(8):23l6-2325.
256. S0 RENSEN JB, STENBYGGARD LE, HANSEN HH et al.: Biweekly paclitaxel, gemcitabine and cisplatin in non-small cell lung cancer (NSCLC). Pmc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:501a
257. PANZA N, FRASCI G, COMELLA P et al.: Cisplatin (P)-gemcitabine (G)-paclitaxel (T) in the treatment of advanced non-small-ccll lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:492a.
258. PAZ-ARES L, SANCHEZ-ROVIRA P, GOMEZ-MARTIN R et al.: A Phase II study of triplet paclitaxel, cisplatin and gemcitabine (Teg) in patients with advanced non-small-cell lung cancer (NSCLC). Pmc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19o46a.
259. COMELLA G, COMELLA P, FRASCI G et al.: Cisplatingenicitabine vs. cisplatin-gcmcitabine-vinorelbine, vs. cisplatin-gcmcitabine-paclitaxel in advanced non-small-cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) Phase III trial. Pmc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:494a.
260. KANO Y, AKUSTU M, TSUNODA S, MORI K, SUZUKI K, ADACHI KI: In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Cbemother. Pharmacol. (1998) 42(2):91-98.
261. PEI XH, NAKANISHI Y, TAKAYAMA K et al: Effect of CPT-11 in combination with other anticanccr agents hi lung cancer cells. Anticancer Drugs (1997) 8(3):231-237.
262. ASAI G, YAMAMOTO N, SAKAI S et al.: Paclitaxel (Taxol) affects pharmacokinetics of irinotecan and its metabolites. Pmc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19;199a.
263. MILLER LL, SOCINSKI MA, SANDLER AB et al: Phase I/II trial of paclitaxel (P), carboplatin (C) and irinotecan (CPT-11) in advanced or metastatic non-small cell lung cancer (NSCLC). Pmc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:475a.
264. AOE K, KIURA K, UEOKA H étal.: Effect of docctaxel with cisplatin or vinorclbine on lung cancer cell lines. Anticancer Res. (1999) 19(lA):291-299.
265. HINO M, KOBAYASHI K, HAYASHIHARA K étal.: In vitro combination effect of docetaxcel (RP5Ö976) with vinca alkaloids on cancer cell line. Pmc.Ann. Meet. Am. Assoc. Cancer Res. (1995) 36:1780a.
266. MILLER VA, GRANT SC, NG K et al.-. Phase I trial of docetaxel (DTX) and vinorejbine (VNR) with filgrastim in patients with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:471a.
267. MILLER VA, KRUG LM, KG KK et al.: Phase U trial of docctaxel and vinorclbine in patients with advanced non-small cell lung cancer. J Clin. Oncol. (2000) 18(6):1346-1350.
268. BALANA C, BARNADAS A, MARTIN C et al,-. A Phase II trial of sequence-dependent docetaxel (D)/vinorelbine (V) DNA damage-induced apoptosis in patients with non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:463a.
269. JOHNSTON1 E, CRAWFORD J, GARST J et al.: Phase I trial of weekly docctaxel (D) and vinorelbinc (V) in advanced non-small cell lung cancer (NSCLC). Proc. Anmi. Meet. Am. Soc. Clin. Oncol. (1999) 18:476a.
270. HOTTON KM, KIM KM, LARSON ML et al: Phase I/II trial of docctaxel and vinorclbine in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:509a.
271. KOUROUSIS C, ANDROULAKIS N, KAKOLYRIS S et al.: First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbinc. Cancer (1998) 83(10):2083-2090.
272. O-ROURKE M, GARFIELD D, ELLIS P: Phase H trial of axotere (T) and Navclbine (N) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:519a.
273. GEORGOULIAS V, ANDROULAKIS N, BOUROS D et al.: Combination chemotherapy with docctaxel, vinorclbinc and cisplatin as first-line treatment of advanced non-small-ccll lung cancer: a multiccnter Phase II study of the Greek Cooperative Group for Lung Cancer. Lung Cancer (1998) 21(3):213-220.
274. ZOLI W, RICOTT1 L, DAL SUSINO M et al.-. Docetaxel and gemcitabinc activity in NSCLC cell lines and in primary cultures from human lung cancer. Br.J. Cancer(.1999) 8100:609-615.
275. SCHLÖ SSER NJJ, RICHELDJ, VAN ZANDWIJK N et al.: Phase I study of docctaxel and gcmcitabine combination chemotherapy in chemotherapy naive patients with advanced or mctastatic non-small cell lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:499a.
276. BILDAT S, HARSTRICK A, GATZEMEIER U et al.: Phase I study of docetaxel in combination with gemcitabinc as first line chemotherapy in patients with mctastatic non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:497a.
277. LAW L, LARA PN JR, REDDY GP et al.-. Salvage gemcitabinc (GEM) in platinum-treated non-small-cell lung cancer (NSCLC): a Phase II California Cancer Consortium trial. Proc. Ann. Meet. Am. Soc. Clin. Oncol.(2000) 19;533a.
278. GARLAND LL, WAGNER H, SHAW GS JR et al.: Phase I study of constant dose rate infusion gemcitabine with Taxoterc in advanced non-small cell lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:504a.
279. SPIRIDONIDIS CH, LAUFMAN LR, JONES VA, WALLANCE K, NICOL S: Phase I study of docctaxcl dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J. Clin. Oncol. (1998) l6(12):3866-3873.
280. RIGAS JR, ROTHENBERG ML, DAVIS TH et al.: Phase I clinical and pharmacokinetic study of docctaxcl in combination with two gemcitabine infusion schedule. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:226a.
281. DUNSFORD ML, MEAD GM, BATEMAN AC, COOK T, TUNG K: Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for mctastatic transitional cell carcinoma. Ann. Oncol. (1999) 10(8):9-43-947.
282. RIZVI NA, SPIR1DONIDIS CH, DAVIS TH et al.: Docetaxel and gemcitabine combinations in non-small cell lung cancer. Semin. Oncol. (1999; 26(5 Suppl. 16):27-31.
283. REBATTU P, QUANTIN X, MORERE J et al.: A Phase II study of docetaxel (D) and gemcitabine (G) combination in patients (Pts) with non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19o39a.
284. PECTASIDES D, ASPROPOTAMITIS A, HALIKIA A et al.: Combination chemotherapy with carboplatin, docetaxel and gemcitabine in advanced non-small-cell lung cancer: a Phase II study. J. Clin. Oncol. (1999) 17(12):38l6-3821.
285. BISSERY MC, VRIGNAUD P, LAVELLE F: In vivo evaluation of the docetaxel-irinotecan combination. Proc. Ann. Meet'Am. Assoc. Cancer Res. (1996) 37:2578a.
286. BISSERY MC, COUTEAU C, OULID-AISSA D, ARMAND JP: Docetaxel in combination with irinotecan: prediction of clinical maximum tolerated dose. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1997) l6:773a.
287. TAKEDA K, NEGORO S, MASUDA N étal.-. Phase I study of docetaxel (Doc) and irinotecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:524a.
288. COUTEAU C, LOKIEC F, VERNILLET L et al.: Phase I dose-finding and pharmacokinetic (PK) study of docctaxcl (D) in combination widi irinotecan (I) in advanced solid tumors. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1997) I6:709a.
289. RICH RS, ARGIRIS A, PECCERILLO K et al.-. Phase I dose escalation trial of weekly docetaxel (D) plus irinotccan (I) in patients with advanced solid tumors. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:225a.
290. ADJEIAA, GOLDBERG RM, RUBINJ et ah A Phase I study of sequential irinotecan (IRN) and docetaxel (DOC) in patients with advanced solid tumors. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1999) 43:603.
291. SENEVIRATNE L, GARCIA AA, ROGERS M et al.-. Phase I clinical and pharmacokinctic (PK) trial of docetaxel (D) and irinotecan (I) administered on a weekly schedule. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:225a
292. ESTEBAN E, LLANO JLG, VIEITEZ JM et al.: Phase I/II study of gcmcitabinc plus vinorelbine in non-smallcell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:482a.
293. GR1DELLI C, FRONTINI L, GULISANO M et at.: Optimal doses of gcmcitabinc + vinorclbinc (Gemvin) in the treatment of advanced non-small-cell lung cancer. A keep-the winner0 Phase 2 study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:477a.
294. LORUSSO V, CARPAGNAKO F, FRASCI G et al.: Phase I/U study of gcmcitabinc plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J. Clin. Oncol. (2000) 18(2):405-U1.
295. KRAJNIK G, WEIN W, GREIL R et al.: Vinorelbinc/gcmcitabinc in advanced non-small cell lung cancer (NSCLC): a Phase I trial. Eur.J. Cancer (1998) 34(12):1977-1980.
296. STEPHENSON J JR, AYLESWORTH C, JOHNSON T et al.-. A Phase I study of gcmcitabine plus vinorelbine on an every other week schedule. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:253a .
297. HERBST R, DANG N, LYNCH C et al: Phase I study of combination weekly gemcitabinc and vinorelbine in patients with lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:488a
298. HARBST RS, KHURI FR, JUNG M et al,-. Phase II study of combination weekly gemcitabinc and vinorelbine in patients with untreated or previously treated non-small-cell lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:462a.
299. CHEN YM, WHANG-PENG J, PERNG RP et al.: A multicenter Phase II study of gcmcitabinc (GEM) and vinorelbine (VNR) in patients with advanced stage IllB-rV non-small-ccll lung cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:481a.
300. PIRKER R, KRAJNIK G, MOHN-STAUDNER A ct al.: Vinorclbinc/gcmcitabinc in advanced non-small-ccll lung cancer (NSCLC): Final results of an AASLC trial. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:529a.
301. HIRSH V, AYOUBJ, CORMIER Y eta!.: Completed Phase II multiccntcr trial with gcmcitabinc and vinorclbinc in patients with advanced (stage IIIB & IV) non-small-ccll lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19o09a.
302. FELIU J, LOPEZ GOMEZ L, MADRONAL C et al.: Gemcitabinc plus vinorelbine in non-small cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group. Cancer (1999) 86(8):1463-1469.
303. FRASCI G, LORUSSO V, PANZA N et al.: Gemcitabine + vinorelbine (GV) yields better survival than vinorelbine (V) alone in elderly non-small cell lung cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) Phase III triaL Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:485a.
304. BARON MG, GARCIA MJ, CHACON JI et al.-. A Phase II study of gemcitabine, cisplatin and vinorelbine in patients with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:469a.
305. DORTA J, MARTIN G, CONSTENLA M et al.: A Phase II study of gemcitabine, cisplatin and vinorelbine in patients with advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:482a.
306. GINOPOULOS P, MASTRONIKOLJS NS, GIANNIOS J et al.: A Phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage Illh-IV non-small cell lung cancer (NSCLC). Lung Ga>r(1999) 23U):31-37.
307. FRASCI G, PANZA N, COMELLA P et al.: Cisplatin, gemcitabine and vinorclbine in locally advanced or mctastatic non-small-cell lung cancer: a Phase I study. Ann. Oncol. (1997) 8(10):l045-lO-48.
308. COMELLA P, FRASCI G, PANZA N et al.: Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group J Clin. Oncol. (2000) 18(7):1451-1457.
309. MOGI H, HASEGAXVA Y, WATANABE A, NOMURA F, SAKA H, SHIMOKATA K: Combination effects of cisplatin, vinorelbine and irinotecan in non-small-ccll lung cancer cell lines in i'itro. Cancer Cbemother. Pbannacol. (1997) 39(3):199-204.
310. BAHADORI HR, OGRETMEN B, ROCHA LIMA CM et al: Evaluation of irinotecan (CPT-11) and gemcitabine (G) as single agents and in combination in small-cell lung cancer cells. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1998) 17:477a
311. ANONYMOUS: Dexamethasone and CPT-11 induce apoptosis in myeloma cells by downregulation of bcl-2 whereas Taxol, mclphalan and gemcitabine induce apoptosis by phosphorylation of bcl-2. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1997) 38:3560a.
312. KANZAWA F, SAIJO N: In vitro interaction between gemcitabine and other anticanccr drugs using a novel three-dimensional model. Semin. Oncol. (1997) 24(Suppl. 7):S7-8-S7-l6.
313. ROCHA LIMA CM, ECKARDT JR, LEOXG SS et al.: Singleagent gemcitabine and gcmcitabinc/irinotccan combination (irimogem) in non-small cell lung cancer. Semin. Oncol. (1999) 26(5 Suppl. 16):43-50.
314. HUSSEIN A, BIRCH R, WALLERJ étal.: Preliminary results of a randomized study comparing paclitaxel and carboplatin (PC) with or without gemcitabine (G) in newly diagnosed non small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:504a.
315. KELLY K, CROWLEY J, BUNN PA, LIVINGSTONE RB, GANDARA DR: A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC). A Southwest Oncology Group (SWOG) TriaL Proc. Am. Soc. Cliti. Oncol. (1999) 18:46la.
316. ROSZKOVi'SKI K: Taxotere® (TXT) versus best supportive care (BSC) in chemonaive patients with unrescctablc non-small cell lung cancer (NSCLC): final results of the Phase III study. Eur. J. Cancer (1999) 35(Suppl. 4):S246.
317. COMELLA P, FRASCI G, DE CATALDIS G et al.-. Cisplatin/carboplatin + ctoposidc + vinorelbine in advanced non-small-ccll lung cancer: a multiccntrc randomised trial. Gruppo Oncologico Campano. Br.J. Cancer (1996) 74(11):1805-1811.
318. COLUCCI G, GEBBIA V, GALETTA D, RICCARDI F, CARIELLO S, GEBBIA N: Cisplatin and vinorelbine followed by ifosfamidc plus cpirubicin vs. the opposite sequence in advanced unresectable stage III and mctastatic stage IV non-small-ccll lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM). Rr. J. Cancer (1994) 76(11):1509-1517.
319. VANSTEENKISTEJ, VANDEBROEKJ, NACKAERTS K et al.: Symptom control in advanced non-small-ccll lung cancer (NSCLC): a multiccntcr prospective randomized Phase III study of single agent gemcitabine (GEM) versus cisplatin-vindesine (PV). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:488a.
320. LOKICH J, ANDERSON N, BERN M et al.: Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionatcd bolus dose schedule for non-small cell lung cancer. Eur.]. Cancer(1998) 34(5);659-663.
321. CROWNJP, DONNELLAN P, O'SULLIVAN C etal.: Phase I/II evaluation of escalating dose docetaxcl (Taxotere, T), ifosfamidc (I) and cisplatin (C) with lenograstim (L) support, in patients with stage III/IV non small cell lung cancer (NSCLCa): an Irish Clinical Oncology Research Group (ICORG) study. Proc. Anmi. Meet. Am. Soc. Clin. Oncol. (1999) 18:477a
322. FUJITA A, TAKABATAKE H, TAGAKI S, SEKINE K: Phase I study of cisplatin, ifosfamidc and irinotccan with rhG-CSF support in advanced non-small cell lung cancer. Oncolog)' (1999) 56(4):301-307.
323. MONNIERA, DOUILLARDJY, LEROUGE D etal: Results of a Phase II study with Taxol (paclitaxel) and Gemzar (gemcitabine) in mctastatic non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:5l6a.
324. BHATIA S, NG E, ANSARI R et al.: A Phase U study of paclitaxel (P) and gemcitabine (G) in patients with advanced non-small-ccll lung cancer - A Hoosicr Oncology Group Study. Proc. Ann. Meet. Am. Soc. Clin. Oitcol. (2000) 19:532a.
325. EDELMAN, G, MELVILLE S, MEYER W, NAPIER S: A multiccnter, Phase II study of combination paclitaxel/gemcitabine in previously untreated, non-resectable, stage HI/IV non-small-cell lung cancer (NSCLC) cancer patients (Pts). Proc. Anim. Meet. Am. Soc. Clin. Oncol. (2000) 19Ö3Ö3.
326. HAINSWORTH JD, BURRIS HA, ERLAND JB el a!.: Phase I/II trial of paclitaxcl by 1-hour infusion, carboplatin and gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer(1999) 85(6):1269-1276.
327. KELLY K, PRINDIVILLE S, BUNN PA et al.: A Phase I study of paclitaxcl (P), carboplatin (C) and gemcitabine (G) in advanced non-small-cell lung cancer (NSCLC): a university of Colorado Cancer Center study. Proc. A nn. Meet. Am. Soc. Clin. Oncol. (1998) 17:490a
328. FAVARETTO A, PACCAGNELLA A, ONIGA F et al.-. Paclitaxcl and carboplatin in combination with gemcitabine (PCG); a Phase I-II trial in non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19:512a.
329. GEORGOULIAS V, KOUROUSIS C, ANDROULAKIS N et al.: Front-line treatment of advanced non-small-ccll lung cancer with docctaxel and gemcitabine: a multicentcr Phase II trial J Clin. Oncol. (1999) 17(3):914-920.
330. SP1RIDONIDIS CH, LAUFMAN LR, CARMAN L et al.-. Second-line chemotherapy with weekly gemcitabine (GEM) and monthly docctaxel (DOC) in patients (Pts) with non-small-cell lung cancer (NSCLC): a Phase II study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2000) 19o03a.
331. BARR F, MISKY H, CLINTHORNE D et al.: A Phase III study of gemcitabine and vinorelbine salvage chemotherapy for taxane resistant non-small-cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:4903.
332. HAINSWORTH JD, DURRIS HA, UTCHY S et al.-. Gemcitabinc and vinorclbine in the second-line treatment of non-small cell lung carcinoma patients. Cancer (2000) 88(6):1353-1358.
333. LAACK E, MENDE T, SAAL JG et al:. A multicenter Phase D trial with gemcitabinc (GEM) and vinorelbine (VNR) in the treatment of non-small-cell lung cancer (NSCLC) stage IIIB and IV. Eur.J. oiH«r(1999) 35(Suppl. 4):S252.
334. CHANG A, BORGS L, ASBURY R et al: Effective salvage treatment for metastatic non-small-cell lung cancer (NSCLC): Combination of gemcitabinc, vinorelbine and cisplatin (GVC). Pmc. Aim. Meet. Am. Soc. Clin. Oncol. (2000) 19:5l4a.
335. GRALLA RJ, RITTENBERG CN, SILVERMAN CR et a!.: gemcitabinc (G) + vinorclbine (V) in combination with mitomycin (M) in non-small-cell lung cancer (NSCLC): results of a Phase I and II study of an active outpatient regimen. Pmc. Ann. Meet. Ain. Soc. Clin. Oncol. (1998) 17:486a.
336. RECCHIAF, DE FILIPPIS S, SAGGIO G étal.-. Phase II study of gemcitabinc, ifosfamidc and vinorclbine in advanced non-small-cell lung cancer. Activity and toxicity of a platinum-free regimen. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:489a.
337. CASTELLANO D, LIANES P, CALZAS J et al.: Non-cisplatin-based chemotherapy for advanced non-small-cell lung cancer (NSCLC): a Phase II study with gemcitabine (G), ifosfamide (I) and vinorelbine (N). Pmc.Aim.Meet.Am.Soc. Clin. O;;coJ.(1998) 17:480a.
338. COMELLA P, FRASCI G, PANZA N et al.: Cisplatin, gemcitabine and vinorclbine combination therapy in advanced non-small-cell lung cancer: a Phase II randomized study of the Southern Italy Cooperative Oncology Group J Clin. O»coJ.(1999) 17(5):152o-1534.